Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Provided By GlobeNewswire
Last update: Aug 7, 2025
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2025.
Read more at globenewswire.com
